Any serious and/or unstable pre-existing medical, psychiatric, or other existing condition that would prevent compliance with the trial or consent process Pre-existing Grade or higher chronic diarrhoea Pre-existing liver disease Pre-existing neuropathy greater than or equal to grade Patients with pre-existing history of or known cardiovascular risk Subjects with pre-existing grade II peripheral neuropathy G> pre-existing peripheral neuropathy Clinically significant peripheral neuropathy at the time of study entry. Patients with pre-existing peripheral neuropathy will be allowed to receive single agent DKN- Pre-existing peripheral neuropathy Grade or higher Pre-existing neuropathy Grade or higher Severe pre-existing ototoxicity or neuropathy that would, in the opinion of the investigator, preclude the use of cisplatin chemotherapy Serious pre-existing medical conditions as follows: < Grade pre-existing peripheral neuropathy per CTCAE Patients with pre-existing grade >= peripheral neuropathy Patients with pre-existing peripheral neuropathy that would limit treatment with taxanes and platinum agents Has pre-existing brain or bone metastatic lesions. Skin condition\r\n* Patients with pre-existing grade or higher ulcerations, fistulas, mucosal lesions, or skin barrier breakdown Exclude patients with pre-existing neuropathy grade or higher Pre-existing and ongoing radiation-related grade bowel or bladder toxicity Patients must have < grade pre-existing peripheral neuropathy (per CTCAE) History of pre-existing immunodeficiency disorder, autoimmune condition, or chronic infection Pre-existing peripheral neuropathy of grade II or higher Pre-existing sensory neuropathy of grade >= Pre-existing grade or neuropathy Pre-existing (active or severe) neurologic disorders (e.g. pre-existing seizure disorder) Pre-existing viral hepatitis Pre-existing neuropathy greater than grade Resectable primary lesion (patients with pre-existing metastasis will be included if their primary is still going to be resected) Pre-existing liver disease Patients with pre-existing retinopathy Pre-existing peripheral neuropathy of severity grade >= (limiting instrumental activities of daily living) Pre-existing neuropathy of >= grade Pre-existing vocal cord paralysis Neurological assessment for pre-existing peripheral neuropathy Patients with pre-existing grade or greater peripheral neuropathy, defined as sensory alteration or paresthesia (including tingling), interfering with function MDS evolving from a pre-existing myeloproliferative neoplasm (MPN) Pre-existing peripheral neuropathy CTCAE grade or worse Subjects with existing periorbital edema Pre-existing peripheral neuropathy grade ?= at registration Pre-existing grade or greater neuropathy Patients with pre-existing grade or higher neuropathy or other serious neurologic toxicity that would significantly increase risk of complications from bortezomib therapy are excluded Pre-existing peripheral neuropathy > grade with pain (CTC version .). Any known pre-existing autoimmune disorder Pre-existing nephritic syndrome Pre-existing grade >= peripheral neuropathy Patients with pre-existing history of or known cardiovascular risk Pre-existing neuropathy of at least Grade Has a pre-existing condition that is contraindicated including Less than Grade pre-existing peripheral neuropathy Pre-existing neuropathy from any cause in excess of Grade . Pre-existing peripheral neuropathy >= Common Terminology Criteria (CTC) grade for those patients who received prior paclitaxel Patients must have recovered from all reversible toxicities related to prior therapy before beginning protocol treatment, and may not have any pre-existing treatment-related toxicities greater than grade ; patients must have < grade pre-existing peripheral neuropathy Patients must have < Grade or pre-existing neuropathy (per CTCAE). Pre-existing Grade greater than (>) neuropathy Pre-existing cardiac conditions Side effects from prior treatment have not resolved to =< grade (or baseline due to previously administered agent/pre-existing conditions) Pre-existing peripheral neuropathy (grade I or higher) Participant has received treatment with cytarabine for a pre-existing myeloid disorder. Patients with Grade or greater pre-existing neurologic abnormalities (CTCAE version .), including Grade or greater peripheral neuropathy caused by previous treatments. Pre-existing carotid artery disease Subjects with pre-existing grade or neuropathy; any peripheral neuropathy must recover to grade =< before enrollment Pre-existing grade or sensory neuropathy Pre-existing neuropathy greater than grade Pre-existing neuropathy greater than grade . Pre-existing neuropathy grade III or greater Pre-existing neuropathy from any cause in excess of Grade Patients with pre-existing maculopathy or retinopathy of the eye Patients who have a pre-existing myopathy Pre-existing peripheral neuropathy >= grade History of pre-existing post-traumatic stress disorder (PTSD) Have serious pre-existing medical conditions. Pre-existing carotid artery disease. Have serious pre-existing medical conditions (at the discretion of the investigator). >= grade pre-existing peripheral neuropathy (per CTCAEv) Pre-existing cancers and/or metastatic disease to the adrenal glands Pre-existing peripheral neuropathy grade >= Ongoing treatment for pre-existing cardiovascular disease Pre-existing neuropathy or severe fluid retention Pre-existing peripheral neuropathy greater than CTCAE Grade . Pre-existing >= grade peripheral neuropathy Pre-existing limitations on care options, (Do Not Attempt Resuscitation Orders, etc). Patients with pre-existing neurologic toxicity > grade (as per CTCAE version .) are not eligible for participation in cohort A; patients screened for participation in cohort B with pre-existing neurologic toxicity > grade (as per CTCAE, version .) are not eligible, unless pre-existing neurologic toxicity is documented in detail and patient's participation in the trial has been approved by the neuro-oncology team at participating institutions Patient has pre-existing peripheral neuropathy Grade > Subject has MDS evolving from a pre-existing myeloproliferative neoplasm (MPN). Pre-existing symmetric peripheral painful neuropathy Pre-existing LE prior to their BC diagnosis Existing CVD Patients with any pre-existing medical conditions that would be a contraindication to exercise EXCLUSION - STUDY : Pre-existing neuropathy including CIPN from prior neurotoxic chemotherapy Pre-existing neutropenia or neutrophil qualitative or quantitative disorder Pre-existing cytopenia or bone marrow failure syndrome Self-reported or documented history of pre-existing peripheral neuropathy due to diabetes, human immunodeficiency virus (HIV), or other conditions Pre-existing active or untreated immunodeficiency disorder and/or chronic use of systemic steroids Patients with pre-existing medical conditions that would be a barrier to exercise Other identified causes of painful paresthesias existing prior to chemotherapy (e.g., radiation or malignant plexopathy, lumbar or cervical radiculopathy, pre-existing peripheral neuropathy of another etiology: e.g., carpal tunnel syndrome, B deficiency, acquired immune deficiency syndrome [AIDS], monoclonal gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism or hypothyroidism, inherited neuropathy, etc.) that might be responsible for the patients current neuropathic symptoms SCREENING PHASE: Pre-existing peripheral neuropathy within days of screening consent INTERVENTION PHASE: Pre-existing peripheral neuropathy within days of screening consent Pre-existing grade or greater neuropathy History of pre-existing peripheral neuropathy prior to chemotherapy, including alcoholism, vitamin B deficiency, diabetes, human immunodeficiency virus (HIV), congenital neuropathy, toxic neuropathy Pre-existing alopecia Patient is using a pre-existing feeding tube for nutritional support at the time of study entry Subject is using a pre-existing feeding tube for nutritional support at study entry. Have pre-existing peripheral neuropathy from other medical conditions or due to cancer Self-reported or documented history of pre-existing peripheral neuropathy prior to initiation of taxane chemotherapy Pre-existing sensory neuropathy > grade